Assessing Antisense Oligonucleotide Apazunersen in Pediatric Angelman Syndrome: The Aspire Study Isabella Ciccone, MPH

Published Date: 30 Dec 2025

Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Vaccine shows promise for pancreatic cancer, study finds

2.

After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.

3.

FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.

4.

"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.

5.

Tumor characteristics found to differ for melanomas in children, teens and young adults


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot